Grapefruit compound may help combat hepatitis C infectionFebruary 05, 2008MGH study reveals mechanism key to maintaining chronic infection, potential therapy target A compound that naturally occurs in grapefruit and other citrus fruits may be able to block the secretion of hepatitis C virus (HCV) from infected cells, a process required to maintain chronic infection. A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) report that HCV is bound to very low-density lipoprotein (vLDL, a so-called "bad" cholesterol) when it is secreted from liver cells and that the viral secretion required to pass infection to other cells may be blocked by the common flavonoid naringenin. If the results of this study extend to human patients, a combination of naringenin and antiviral medication might allow patient to clear the virus from their livers. The report will appear in an upcoming issue of the journal Hepatology and has been released online.
"By finding that HCV is secreted from infected cells by latching onto vLDL, we have identified a key pathway in the viral lifecycle," says Yaakov Nahmias, PhD, of the MGH-CEM, the paper's lead author. "These results suggest that lipid-lowering drugs, as well as supplements, such as naringenin, may be combined with traditional antiviral therapies to reduce or even eliminate HCV from infected patients" HCV is the leading cause of chronic viral liver disease in the United States and infects about 3 percent of the world population. Current antiviral medications are effective in only half of infected patients, 70 percent of whom develop chronic infection that can lead to cirrhosis or liver cancer. Since the virus does not integrate its genetic material into the DNA of infected cells the way HIV does, totally clearing the virus could be possible if new cells were not being infected by secreted virus. "Identifying the route by which HCV is released from cells introduces a new therapeutic target," says Martin Yarmush, MD, PhD, director of the MGH-CEM and the paper's senior author. "That pathway's dependence on cholesterol metabolism could allow us to interfere with viral propagation to other cells and tissues, using tools already developed for atherosclerosis treatment." Yarmush is the Helen Andrus Benedict Professor of Surgery and Bioengineering at Harvard Medical School (HMS). Grapefruit's bitter taste is caused the presence of the flavonoid naringin, which is metabolized into naringenin, an antioxidant previously reported to help lower cholesterol levels. Considerable research has suggested that HCV infects liver cells by, in essence, "hitching a ride" onto the natural lipoprotein-cholesterol metabolic pathway. Since earlier evidence has shown that naringenin can reduce secretion of vLDL from liver cells, the researchers examined whether the compound might also lower HCV secretion from infected cells. Their experiments confirmed that naringenin does reduce the secretion of HCV from infected cell lines and showed that the compound inhibits the mechanism for secreting a specific lipoprotein that binds HCV. "This work presents the possibility that non-toxic levels of a dietary supplement, such as naringenin, could effectively block HCV secretion," says Raymond Chung, MD, MGH director of Hepatology and one of the study authors, "This approach might eventually be used to treat patients who do not respond to or cannot take traditional interferon-based treatment or be used in combination with other agents to boost success rates." Massachusetts General Hospital Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. CPAP Arctic Ocean Urinary Incontinence Radiation Head And Neck Cancer Dead Zone Bone Marrow Yellowstone Nanotechnology Lead Exposure Learning Carbon Monoxide Cosmic Rays Hearing Video Games Blood Vessel Embryonic Stem Cell Autism Amyloid-beta Hiv Vaccine Bone Loss Soybean Bipolar Disorder Drugs Meningitis
See More: Science News Tags | |||||||||||||||||||||
|
Related Hepatitis Current Events and Hepatitis News Articles Young offenders' health critical to rehabilitation The physical and mental health needs of juvenile offenders should be treated as a priority if offenders held in detention have any real hope of rehabilitation, according to new research from the University of Adelaide, Australia. Transplant drug stimulates immune memory Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered. Good news for some hard-to-treat hepatitis C patients In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. FibroTest attributes to generate decision trees in hepatitis C In recent years the use of non-invasive biomarkers to assess liver fibrosis has become widely accepted. DKK-3 and WIF-1: Proteins related to liver cancer development? Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year. Low-fat diet helps genetically predisposed animals avoid liver cancer In a study comparing two strains of mice, one susceptible to developing cancer and the other not, researchers found that a high-fat diet predisposed the cancer-susceptible strain to liver cancer, and that by switching to a low-fat diet early in the experiment, the same high-risk mice avoided the malignancy. Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawal Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status. NEJM Study Points to New Era in Hepatitis C Treatment For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone. MicroRNAs grease the cell's circadian clockwork Most of our cells possess an internal clock, a group of genes displaying a cyclic expression pattern that reaches a peak once a day. Liver disease 'shrunk' by blood-pressure drug A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients. More Hepatitis Current Events and Hepatitis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||